Monopar Therapeutics to Present at Upcoming Investor Conferences in September

Monopar Therapeutics Inc. (Nasdaq: MNPR) announced that its CEO, Chandler D. Robinson, will present an overview of the company at two upcoming investor conferences in September 2021.

Rhea-AI Summary

Monopar Therapeutics Inc. (Nasdaq: MNPR) announced that its CEO, Chandler D. Robinson, will present an overview of the company at two upcoming investor conferences in September 2021. The first presentation will be at the H.C. Wainwright 23rd Annual Global Investment Conference on September 13, 2021, at 7:00 a.m. ET. The second will occur at the Cantor Virtual Global Healthcare Conference 2021 on September 30, 2021, at 11:20 a.m. ET. Monopar focuses on developing therapeutics aimed at extending life and improving the quality of life for cancer patients.

Argus Session date unavailable

+9.89% session move Open Argus

Details

News Market Reaction – MNPR

The recorded move for MNPR in the trading session of this news was +9.89%.

Data tracked by StockTitan Argus. Session date unavailable.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

WILMETTE, Ill., Sept. 09, 2021 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (Nasdaq: MNPR), a clinical-stage biopharmaceutical company primarily focused on developing proprietary therapeutics designed to extend life or improve the quality of life for cancer patients, today announced that Chandler D. Robinson, MD, Chief Executive Officer, is scheduled to present a Company overview at the following investor conferences in September:

H.C. Wainwright 23^rd Annual Global Investment Conference 
The Company’s presentation will be webcast on Monday, September 13, 2021 at 7:00 a.m. ET 

Cantor Virtual Global Healthcare Conference 2021 
The Company’s presentation will be webcast on Thursday, September 30, 2021 at 11:20 a.m. ET, Track 7

About Monopar Therapeutics Inc. 

Monopar Therapeutics is a clinical-stage biopharmaceutical company primarily focused on developing proprietary therapeutics designed to extend life or improve the quality of life for cancer patients. Monopar's pipeline consists of Validive for the prevention of chemoradiotherapy-induced severe oral mucositis in oropharyngeal cancer patients; camsirubicin for the treatment of advanced soft tissue sarcoma; a late-stage preclinical antibody, MNPR-101, for advanced cancers and severe COVID-19; and an early-stage camsirubicin analog, MNPR-202, for various cancers. For more information, visit: www.monopartx.com.

CONTACT:  

Monopar Therapeutics Inc.
Investor Relations  
Kim R. Tsuchimoto  
Chief Financial Officer  
kimtsu@monopartx.com  

Follow Monopar on social media for updates: 

Twitter: @MonoparTx  LinkedIn: Monopar Therapeutics

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

When will Monopar Therapeutics present at the H.C. Wainwright conference?

Monopar Therapeutics will present at the H.C. Wainwright 23rd Annual Global Investment Conference on September 13, 2021, at 7:00 a.m. ET.

What is the date and time for Monopar's presentation at the Cantor Global Healthcare Conference?

The presentation at the Cantor Virtual Global Healthcare Conference 2021 will take place on September 30, 2021, at 11:20 a.m. ET.

What is the focus of Monopar Therapeutics?

Monopar Therapeutics focuses on developing proprietary therapeutics designed to extend life and improve the quality of life for cancer patients.

Who is the CEO of Monopar Therapeutics?

The CEO of Monopar Therapeutics is Chandler D. Robinson.

What therapeutic candidates are in Monopar's pipeline?

Monopar's pipeline includes Validive, camsirubicin, MNPR-101, and MNPR-202, targeting various cancers and treatment-related conditions.